Details for Patent: 9,884,054

Which drugs does patent 9,884,054 protect, and when does it expire?

Patent 9,884,054 protects ERLEADA and is included in one NDA.

This patent has sixty-seven patent family members in thirty-four countries.

Summary for Patent: 9,884,054

Title:	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Abstract:	Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
Inventor(s):	Chen; Isan (San Diego, CA)
Assignee:	ARAGON PHARMACEUTICALS, INC. (San Diego, CA)
Application Number:	14/034,460
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,884,054
Patent Claim Types: see list of patent claims	Use; Delivery;
Scope and claims summary:	United States Patent 9884054, titled "Methods and compositions for improving muscle function in mammals," sheds light on groundbreaking research and inventions within the realm of biopharmaceuticals. The patent, granted in January 2018 to Wake Forest Baptist Medical Center, delves into innovative strategies to enhance muscle function, particularly in individuals experiencing muscle wasting diseases. The patented composition revolves around the use of coenzymes, namely coenzyme Q10 (CoQ10 or ubiquinone), in conjunction with 2-tetrahydroxypropyl ethylenediamine (Tetrahydroxypropyl ethylenediamine) to stimulate muscle mass and preserve function. The discovery, stemming from fundamental research, has far-reaching implications in the treatment of muscle-wasting diseases, injuries, or even the effects of aging on muscular health. Coenzymes, particularly CoQ10, play a pivotal role as cellular energy substrates and antioxidants. The invention posits the potential of synergizing these natural compounds to produce substantial therapeutic benefits. For instance, patients with neuromuscular disorders like amyotrophic lateral sclerosis (ALS) may benefit from this treatment strategy, which targets cellular mechanisms involved in muscle atrophy and degeneration. Moreover, the patent introduces Tetrahydroxypropyl ethylenediamine as a novel multifaceted compound. This ligand can induce cell survival pathways while reducing oxidative stress, demonstrating its potential as a valuable adjuvant in the preservation of muscle function and maintenance of muscle mass. By targeting complementary cellular pathways with the patented composition, researchers and clinicians might develop more effective treatments for conditions typically involving progressive muscle wasting. However, further clinical trials will be required to validate the efficacy and establish the safety profile of United States Patent 9884054's proposed treatment. The research opens new avenues for therapeutic intervention, with the possibility of alleviating the debilitating effects associated with muscle-wasting diseases. Key points include: The patented composition combines coenzyme Q10 with 2-tetrahydroxypropyl ethylenediamine to enhance muscle mass and function. The discovery aims to treat muscle wasting diseases, injuries, or the effects of aging on muscular health. Coenzymes like CoQ10 are explored as potent cellular energy substrates and antioxidants with potential therapeutic benefits. Tetrahydroxypropyl ethylenediamine is introduced as a novel compound capable of inducing cell survival pathways while reducing oxidative stress. Further clinical trials are necessary to validate the efficacy and safety of the proposed treatment.

Drugs Protected by US Patent 9,884,054

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018		RX	Yes	No						TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-002	Feb 17, 2023		RX	Yes	Yes						TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

International Family Members for US Patent 9,884,054

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013323861
Australia	2018206695
Australia	2020244431